» Articles » PMID: 36004008

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy

Overview
Publisher Dove Medical Press
Date 2022 Aug 25
PMID 36004008
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Pharmacogenetic counselling is a complex task and requires the efforts of an interdisciplinary team, which cannot be implemented in most cases. Therefore, simple rules could help to minimize the risk of medications incompatible with each other or with frequent genetic variants.

Patients And Methods: One hundred and eighty-four multi-morbid Caucasian patients suffering from side effects or inefficient therapy were enrolled and genotyped. Their medication was analyzed by a team of specialists using Drug-PIN (medication support system) and individual recommendations for 34 drug classes were generated.

Results: In each of the critical drug classes, 50% of the drugs cannot be recommended to be prescribed in typical drug cocktails. PPIs and SSRI/SNRIs represent the most critical drug classes without showing a single favorable drug. Among the well-tolerated drugs (not recommended for less than 5% of the patients) are metamizole, celecoxib, olmesartan and famotidine. For each drug class, a ranking of active ingredients according to their suitability is presented.

Conclusion: Genotyping and its profound analysis are not available in many settings today. The consideration of frequent alterations of metabolic elimination routes and drug-drug-gene interactions by using simple rankings can help to avoid many incompatibilities, side effects and inefficient therapies.

Citing Articles

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M NPJ Breast Cancer. 2024; 10(1):58.

PMID: 39019916 PMC: 11254918. DOI: 10.1038/s41523-024-00657-z.


Frequencies of Combined Dysfunction of Cytochromes P450 2C9, 2C19, and 2D6 in an Italian Cohort: Suggestions for a More Appropriate Medication Prescribing Process.

Gentile G, De Luca O, Del Casale A, Salerno G, Simmaco M, Borro M Int J Mol Sci. 2023; 24(16).

PMID: 37628884 PMC: 10454797. DOI: 10.3390/ijms241612696.

References
1.
Roots I, Gerloff T, Meisel C, Kirchheiner J, Goldammer M, Kaiser R . Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev. 2004; 36(3-4):617-38. DOI: 10.1081/dmr-200033458. View

2.
van Kuilenburg A . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004; 40(7):939-50. DOI: 10.1016/j.ejca.2003.12.004. View

3.
Holt S, Schmiedl S, Thurmann P . Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010; 107(31-32):543-51. PMC: 2933536. DOI: 10.3238/arztebl.2010.0543. View

4.
Koverech A, Soldati V, Polidori V, Pomes L, Lionetto L, Capi M . Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach. Int J Environ Res Public Health. 2018; 15(8). PMC: 6122067. DOI: 10.3390/ijerph15081634. View

5.
Bertholee D, Maring J, van Kuilenburg A . Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet. 2016; 56(4):317-337. PMC: 5340837. DOI: 10.1007/s40262-016-0450-z. View